Program
Decitabine
Also written as “decitabine”, “decitabine (5-aza-2'deoxycytidine)” and “IV Decitabine”.
Its studies are mostly in Myelodysplastic Syndromes · Leukemia, Myeloid, Acute · Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Lymphoma, T-Cell, Peripheral · Leukemia, Myeloid, led by 9 companies.
Drug pageDecitabine: every studyMany companies study it; this page follows only the 28 they lead. All 277 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eisaiits history only | 90 open or running | phase 4since Nov 5, 2009 | Nov 28, 2005 | none ahead |
| Otsukaits history only | 82 open or running | phase 3since Aug 8, 2002 | Jul 19, 2002 | none ahead |
| EpiDestinyits history only | 30 open or running | phase 1since Jan 31, 2019 | Jan 31, 2019 | none ahead |
| Johnson & Johnsonits history only | 30 open or running | phase 2since Aug 29, 2008 | Aug 29, 2008 | none ahead |
| AbbVieits history only | 10 open or running | phase 3since May 3, 2019 | May 3, 2019 | none ahead |
| Dong Wha Pharmaceuticalits history only | 10 open or running | phase 1since Sep 8, 2017 | Sep 8, 2017 | none ahead |
| Imunopharm Technologyits history only | 10 open or running | phase 1since May 14, 2018 | May 14, 2018 | none ahead |
| Sino Biopharmaceuticalits history only | 10 open or running | phase 4since Dec 9, 2013 | Dec 9, 2013 | none ahead |
| Treebough Therapiesits history only | 11 open or running | phase 1since May 20, 2025 | May 20, 2025 | Dec 30, 2026phase 1 · NCT07006025 |
Also a collaborator on its studies: dsm-firmenich.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 14 studies since Jul 19, 2002.
- Aug 5, 2010Phase 2 study in Pediatric Acute Myelogenous Leukemia (AML)Eisai · NCT01177540 · 25 enrolled · United States, Australia, Canada
- May 10, 2013Phase 2 study in Leukemia, Myeloid, AcuteJohnson & Johnson · NCT01853228 · 17 enrolled · Belgium, Denmark, France and more
- Dec 9, 2013Sino Biopharmaceutical’s first study: phase 4 study in Myelodysplastic SyndromesNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT02013102 · 240 enrolled · China
- Mar 20, 2014Phase 2 study in Myelodysplastic SyndromesOtsuka · NCT02103478 · 130 enrolled · United States, Canada
- Sep 8, 2017Dong Wha Pharmaceutical’s first study: phase 1 study in Advanced Breast CancerNew to Dong Wha PharmaceuticalDong Wha Pharmaceutical · NCT03282825 · 18 enrolled · Korea, Republic of
- May 14, 2018Imunopharm Technology’s first study: phase 1 study in NHLNew to Imunopharm TechnologyImunopharm Technology · NCT03535753 · 50 enrolled · China
- Jan 31, 2019EpiDestiny’s first study: phase 1 study in HealthyNew to EpiDestinyEpiDestiny · NCT03828084 · 16 enrolled · United States
- May 3, 2019AbbVie’s first study: phase 3 study in Leukemia, Myeloid, AcuteNew to AbbVieAbbVie · NCT03941964 · 60 enrolled · United States
- Sep 10, 2019Phase 1 study in HealthyEpiDestiny · NCT04086238 · 46 enrolled · United States
- May 23, 2022Phase 1 study in Lymphoma, T-Cell, PeripheralOtsuka · NCT05403450 · 33 enrolled · United States, Australia, France and more
- Mar 31, 2023Phase 1 study in HealthyEpiDestiny · NCT05816356 · 10 enrolled · United States
- Apr 25, 2023Phase 3 study in Myelodysplastic SyndromesOtsuka · NCT05883956 · 13 enrolled · Australia, New Zealand
- Sep 22, 2023Phase 2 study in Myelodysplastic SyndromesOtsuka · NCT06091267 · 72 enrolled · China
- May 20, 2025Treebough Therapies’ first study: phase 1 study in MDSNew to Treebough TherapiesTreebough Therapies · NCT07006025 · 20 planned · United States
Ahead
- Dec 30, 2026Primary completion: phase 1 study in MDSTreebough Therapies · NCT07006025
TargetBeta
“DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor; DNA inhibitor”ChEMBL 37, by rule
Studies
All 28 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07006025MDS · United States | 1 | Recruiting | Treebough Therapies | Dec 30, 2026 | 20 |
| NCT06091267Myelodysplastic Syndromes · China | 2 | Active, not recruiting | Otsuka | May 22, 2026 | 72 |
| NCT05883956Myelodysplastic Syndromes · Australia, New Zealand | 3 | Active, not recruiting | Otsuka | Dec 6, 2024 | 13 |
| NCT05816356Healthy · United States | 1 | Completed | EpiDestiny | Jun 30, 2023 | 10 |
| NCT05403450Lymphoma, T-Cell, Peripheral · United States, Australia, France and more | 1 | Terminated | Otsuka | Dec 16, 2024 | 33 |
| NCT04086238Healthy · United States | 1 | Completed | EpiDestiny | Nov 21, 2019 | 46 |
| NCT03941964Leukemia, Myeloid, Acute · United States | 3 | Completed | AbbVie | Mar 14, 2022 | 60 |
| NCT03828084Healthy · United States | 1 | Completed | EpiDestiny | May 2, 2019 | 16 |
| NCT03535753NHL · China | 1 | UNKNOWN | Imunopharm Technology | Sep 1, 2020 | 50 |
| NCT03282825Advanced Breast Cancer · Korea, Republic of | 1 | UNKNOWN | Dong Wha Pharmaceutical | Feb 2018 | 18 |
| NCT02103478Myelodysplastic Syndromes · United States, Canada | 2 | Completed | Otsuka | Jun 5, 2018 | 130 |
| NCT02013102Myelodysplastic Syndromes · China | 4 | UNKNOWN | Sino Biopharmaceutical | Dec 2015 | 240 |
| NCT01853228Leukemia, Myeloid, Acute · Belgium, Denmark, France and more | 2 | Terminated | Johnson & Johnson | Aug 28, 2017 | 17 |
| NCT01177540Pediatric Acute Myelogenous Leukemia (AML) · United States, Australia, Canada | 2 | Terminated | Eisai | Jul 19, 2013 | 25 |
| NCT01011283Myelodysplastic Syndromes · United States | 4 | Terminated | Eisai | Jan 2011 | 26 |
| NCT00941109Myelodysplastic Syndromes · United States | 1 | Completed | Eisai | Sep 2011 | 12 |
| NCT00796003Myelodysplastic Syndromes · Japan | 1 | Completed | Johnson & Johnson | Oct 2010 | 39 |
| NCT01378416Leukemia · United States | 1 | Completed | Eisai | Jan 2006 | 16 |
| NCT00760084Leukemia, Myeloid, Acute · United States | 2 | Completed | Eisai | Sep 2005 | 10 |
| NCT00744757Myelodysplastic Syndromes · Taiwan | 2 | Completed | Johnson & Johnson | Sep 2010 | 37 |
| NCT00619099Myelodysplastic Syndromes · United States | 2 | Completed | Eisai | Mar 2012 | 67 |
| NCT00358644Leukemia, Myeloid, Acute · United States | 2 | Completed | Eisai | Feb 2008 | 55 |
| NCT00282399Myelodysplastic Syndromes · United States | 1 | Terminated | Eisai | Oct 2008 | 41 |
| NCT00260065Myelodysplastic Syndromes · United States, Canada | 2 | Completed | Eisai | Jun 2008 | 99 |
| NCT00043381Myelodysplastic Syndromes · United States | 3 | Completed | Otsuka | Nov 2002 | 160 |
| NCT00042016Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Canada | 2 | Completed | Otsuka | 40 | |
| NCT00042003Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Canada | 2 | Completed | Otsuka | Dec 2004 | 40 |
| NCT00041990Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Canada | 2 | Completed | Otsuka | 40 |
How it is read
Names in the registry
- “Decitabine”, 14 entries
- “decitabine”, 8 entries
- “decitabine (5-aza-2'deoxycytidine)”, 4 entries
- “IV Decitabine”, 1 entry
- “Decitabine + Cedazuridine”, 1 entry
Conditions, from the studies’ own filings
- Myelodysplastic Syndromes, 13 studies
- Leukemia, Myeloid, Acute, 7 studies
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive, 2 studies
- Lymphoma, T-Cell, Peripheral, 1 study
- Leukemia, Myeloid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.